Shardul Amarchand Mangaldas & Co. (SAM) advised Meesho Limited (“Meesho”) on its landmark ₹5,421 crore (approx. US$ 600 million) Initial Public Offering, comprising a fresh issue and an offer for sale by the promoters, Vidit Aatrey and Sanjeev Kumar, and other selling shareholders including affiliates of Elevation Capital, Peak XV, Y Combinator and others.  … Read More +

Shardul Amarchand Mangaldas & Co. (SAM) advised Biocon Limited (“BL”) and its subsidiary Biocon Biologics Limited (“BBL”) on their ~USD 1.2 billion integration, involving BL’s acquisition of minority shareholdings in BBL from Viatris, Serum Institute Lifesciences, Tata Capital Growth Fund II and True North.   The Transaction Team was led by Raghubir Menon, Partner and… Read More +

Shardul Amarchand Mangaldas advised KKR on all aspects of their acquisition for their inter-fund transfer involving Lighthouse Learning Private Limited (LHL).   The SAM advised on all aspects of the transaction structuring and the acquisition.   The SAM team was led by Raghubir Menon, Regional Practice Head – M&A and Private Equity, supported by Partners… Read More +

Shardul Amarchand Mangaldas & Co. (SAM) advised Steadview Capital Mauritius Limited on its pre-IPO secondary purchase of equity shares of Wakefit Innovations Limited from Verlinvest S.A.   The transaction forms part of a broader pre-IPO round ahead of Wakefit’s proposed public listing, for which the company filed its red herring prospectus with the Registrar of… Read More +